SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 1,953,472 shares, a growth of 21.1% from the February 26th total of 1,613,558 shares. Based on an average daily volume of 918,838 shares, the days-to-cover ratio is currently 2.1 days. Approximately 5.1% of the shares of the company are sold short.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the third quarter worth approximately $32,000. State of Wyoming bought a new position in SAB Biotherapeutics in the fourth quarter worth approximately $34,000. Virtu Financial LLC acquired a new stake in SAB Biotherapeutics in the third quarter valued at approximately $40,000. Finally, State Street Corp acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $49,000. Institutional investors own 7.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SABS shares. UBS Group initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price on the stock. Guggenheim began coverage on SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 price target for the company. Chardan Capital increased their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

SAB Biotherapeutics Price Performance

SABS traded up $0.07 on Tuesday, reaching $3.85. The stock had a trading volume of 188,128 shares, compared to its average volume of 565,113. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $196.16 million, a price-to-earnings ratio of -1.66 and a beta of 0.59. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The firm has a 50-day moving average of $4.02 and a 200-day moving average of $3.51.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.